Staub v. Eastman Kodak Co.

726 A.2d 955, 320 N.J. Super. 34
CourtNew Jersey Superior Court Appellate Division
DecidedApril 5, 1999
StatusPublished
Cited by41 cases

This text of 726 A.2d 955 (Staub v. Eastman Kodak Co.) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Staub v. Eastman Kodak Co., 726 A.2d 955, 320 N.J. Super. 34 (N.J. Ct. App. 1999).

Opinion

726 A.2d 955 (1999)
320 N.J. Super. 34

Joseph STAUB and Dorothy Staub, Plaintiffs-Appellants,
v.
EASTMAN KODAK COMPANY, Alcon Pharmaceutical Laboratories, Inc., Alcon (Puerto Rico), Inc., Lafayette Pharmaceutical, Inc., and Lafayette Pharmacal, Inc., Defendants-Respondents.

Superior Court of New Jersey, Appellate Division.

Argued December 1, 1998.
Decided April 5, 1999.

*956 Wayne D. Greenstone, Newark, for plaintiffs-appellants (Greenstone & Greenstone, attorneys; Mr. Greenstone, on the brief).

Thomas J. Alworth and George A. Joseph, of the Chicago bar, admitted pro hac vice for Kirkland & Ellis, Chicago, IL, for defendants-respondents (Shanley & Fisher, attorneys, Morristown, and Kirkland & Ellis, attorneys; Mr. Alworth, Mr. Joseph, and Ellen Therese Ahern, Chicago, IL, on the brief).

Before Judges PRESSLER, BROCHIN and STEINBERG.

The opinion of the court was delivered by BROCHIN, J.A.D.

Plaintiffs Joseph Staub and Dorothy Staub, his wife, allege that Mr. Staub suffers from arachnoiditis, a debilitatingly painful inflammation of the membrane surrounding the spinal cord. He claims to have developed this condition as the result of having been injected with Pantopaque, a radiopaque substance used as a contrast medium for myelography, a process for the x-ray visualization of the spinal cord. Defendants manufactured or distributed Pantopaque. Mr. Staub seeks damages from defendants as compensation for his condition because he alleges Pantopaque is a defective product. Although his complaint pleads failure to warn, defective manufacturing and defective design, his appellate brief suggests that he is relying exclusively on his contention that defendants failed to warn that Pantopaque could cause arachnoiditis.[1]*957 Mr. Staub was injected with Pantopaque on four occasions, in March 1972, March 1978, September 1979, and December 1981. He commenced this action on March 31, 1994. Claiming that Mr. Staub knew or should have known long before March 31, 1992, of the facts on which he bases his cause of action, defendants moved for summary judgment dismissing his complaint on the ground that his suit was barred by the twoyear statute of limitations, N.J.S.A. 2A:14-2.[2]

Mr. Staub advanced the same arguments in opposition to the summary judgment motion that he has asserted before us. He contends that his cause of action did not accrue until he knew that his condition was attributable to the fault of another, and that he acquired that knowledge for the first time on September 9, 1993, when Dr. John J. Sweeney, a Department of Veterans' Affairs physician who had been treating him since some time before March 25, 1992, wrote in a letter addressed "To Whom it may Concern" that Mr. Staub "is presently under my care and being treated for arachnoiditis which has been confirmed by MRI." Alternatively, Mr. Staub asserts that the period of limitations for commencing his suit was tolled by the filing of a putative class action in the United States District Court for the District of New Jersey on August 28, 1990 on behalf of two classes of potential plaintiffs, "All persons in the United States who received one or more Pantopaque myelograms and subsequently [(1) ] have been diagnosed with Arachnoiditis [or (2) who have] symptoms of arachnoiditis [and] ... to date[ ] have not been diagnosed with arachnoiditis," and that the tolling continued until the district court denied class certification on August 28, 1992. We will consider each of these arguments in turn.

Mr. Staub has suffered from back pain at least since 1971, when he injured his back, right leg, and shoulder as the result of a fall from a ladder. Since that time, his pain has become steadily more severe and debilitating. Following a further injury resulting from an accident which he sustained on July 20, 1979 while operating a tractor at a construction site, he experienced acute pain in his back, right leg and right knee, numbness and tingling in his right leg, pain radiating down both legs and severe and extensive emotional and neurological injuries. He has not been able to work since that accident. Lumbar spine surgery on four occasions, most recently in December 1979, failed to alleviate his condition.

On June 21, 1990, the "Geraldo" show on television dealt with "Time-bomb Drugs." Pantopaque was one of the three drugs which were the subject of the program. Ms. Staub watched the entire program. Mr. Staub watched at least parts of it. Two of the guests who appeared on the show claimed to be suffering from arachnoiditis that had resulted from injections of Pantopaque. One of the guests said that the Pantopaque which caused her injury had been administered to her in connection with a myelogram. The host of the program mentioned Alcon Labs as the manufacturer of Pantopaque, explained that Pantopaque is "like a dye ... that they inject into your spine so they can take an X-ray or a picture of your spine for suspected injury," and he introduced an attorney who, he said, was "handling many of these Pantopaque cases." Both of the arachnoiditis sufferers on the program described symptoms which were the same as Mr. Staub's. Toward the end of the show, the host gave the address of one of the guests who would "serv[e] as the clearinghouse for... inquiries" from "people who are alleging some after effects or side effects or suspecting some from the drug Pantopaque," and he summarized comments about the apparent connection between Pantopaque and the back and leg pains which the guests described:

So, if any of you have had a myelogram, then you've had, probably, the Pantopaque. So, if you have the symptoms that have been described here ... just remember that. If you have some unexplained symptoms, this may be one of the reasons.

*958 Mr. and Mrs. Staub discussed the program after it had concluded. She said to her husband, "We found out why you can't go back to work." He testified that he came to an "understanding of what arachnoiditis can do to people" by "catching the end, really, of the `Geraldo' show."

Mr. Staub wrote to the "clearinghouse" address provided on the "Geraldo" show. His brief to our court states, "Mr. Staub wrote to the Arachnoiditis Information Support Network for information, which was sent at some time during 1990, although it is unclear precisely when any of this information was received." He testified that he received the materials from the Arachnoiditis Foundation when his wife wrote for them after the "Geraldo" show. He learned the names of the manufacturers of Pantopaque either from these materials or from someone associated with the Arachnoiditis Foundation.

On August 28, 1990, a putative class action seeking damages and other relief was filed in the United States District Court for the District of New Jersey against the same parties who are defendants in the present suit. We have not been furnished with a copy of the complaint in that suit, but the District Court's opinion denying class certification indicates that the theory of the case was that Pantopaque was a defective product which had caused persons using it to develop arachnoiditis. Mr. Staub learned of the class action from information which he received from the Arachnoiditis Foundation. He claims to have signed a retention letter retaining the attorneys representing plaintiffs in the class action. The record submitted to us does not show the date of the retention letter. But Mr. Staub testified that "for two years I kept getting letters....

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Janet Doe v. City of Memphis, Tennessee
Court of Appeals of Tennessee, 2024
McLeod v. Pershing LLC
N.D. Texas, 2024
Jane Doe 8 v. Chiquita Brands International, Inc.
48 F.4th 1202 (Eleventh Circuit, 2022)
Kim v. Harte Hanks, Inc.
S.D. New York, 2019
Chavez v. Occidental Chem. Corp.
300 F. Supp. 3d 517 (S.D. Illinois, 2018)
Patrickson v. Dole Food Company, Inc.
368 P.3d 959 (Hawaii Supreme Court, 2015)
Cedillo v. TransCor America, LLC
131 F. Supp. 3d 734 (M.D. Tennessee, 2015)
Herschel Zarecor v. Morgan Keegan & Company
801 F.3d 882 (Eighth Circuit, 2015)
Rader v. Greenberg Traurig, LLP
352 P.3d 465 (Court of Appeals of Arizona, 2015)
Dow Chemical Corp. v. Blanco
67 A.3d 392 (Supreme Court of Delaware, 2013)
Patterson v. Novartis Pharmaceuticals Corp.
909 F. Supp. 2d 116 (D. Rhode Island, 2012)
Quinn v. Louisiana Citizens Property Insurance Corp.
118 So. 3d 1011 (Supreme Court of Louisiana, 2012)
Seaboard Corp. v. Marsh Inc.
284 P.3d 314 (Supreme Court of Kansas, 2012)
Schmidt v. CELGENE CORP.
42 A.3d 892 (New Jersey Superior Court App Division, 2012)
Stevens v. Novartis Pharmaceuticals Corp.
2010 MT 282 (Montana Supreme Court, 2010)
Brodin v. Merck & Co.
694 F. Supp. 2d 253 (S.D. New York, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
726 A.2d 955, 320 N.J. Super. 34, Counsel Stack Legal Research, https://law.counselstack.com/opinion/staub-v-eastman-kodak-co-njsuperctappdiv-1999.